Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

A double-blind, placebo controlled, randomized, phase II study evaluating the efficacy and safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus capmatinib and placebo as first line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping (METΔex14) mutations

Key facts

Study ID

NCT04323436

Run by

Novartis Pharmaceuticals

People needed

31

Starts

2020-08-19

Expected to finish

2023-01-26

Last updated by the study team

2024-10-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Massachusetts General Hospital Liver and Kidney TX — Boston, Massachusetts, United States
• Novartis Investigative Site — Leuven, Belgium
• Novartis Investigative Site — Montreal, Quebec, Canada
• Novartis Investigative Site — Lille, France
• Novartis Investigative Site — Paris, France
• Novartis Investigative Site — Pierre-Bénite, France
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Cologne, Germany
• Novartis Investigative Site — Gerlingen, Germany
• Novartis Investigative Site — Tübingen, Germany
• Novartis Investigative Site — Bologna, BO, Italy
• Novartis Investigative Site — Ōsaka-sayama, Osaka, Japan
• Novartis Investigative Site — Seoul, South Korea
• Novartis Investigative Site — Barcelona, Catalonia, Spain
• Novartis Investigative Site — Valencia, Valencia, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.